In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 2, 1999, Pages 193-197

  Yardley, Vanessa ^a   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BENZNIDAZOLE; DRUG CARRIER; NIFURTIMOX;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; TRYPANOSOMA CRUZI;

ANIMALIA; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0032801314     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.193     Document Type: Article

References (36)

1. WHO, 1991. Control of Chagas' disease. World Health Organ Tech Rep Ser: 811.
2. Yoshida N, Schenkman S, 1997. American trypanosomiasis. Curr Opin Infect Dis 10: 351-356.
3. de Castro SL, 1993. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop 53: 83-98.
4. Docampo R, Schmuñis GA, 1997. Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas' disease. Parasitol Today 13: 129-130.
5. Chance ML, Goad LJ, 1997. Sterol metabolism of Leishmania and trypanosomes: potential for chemotherapeutic exploitation. Hide G, Mottram JC, Coombs GH, eds. Trypanosomiasis and Leishmaniasis; Biology and Control. Wallingford, United Kingdom: CAB International Publications, 163-176.
6. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, Lazardi K, Piras MM, Piras R, Perez N, Wincker P, Ryley JF, 1996. Cure of short-and long-term experimental Chagas' disease using D0870. Science 273: 969-971.
7. Croft SL, Walker JJ, Gutteridge WE, 1988. Screening of drugs for rapid activity of against Trypanosoma cruzi trypomastigotes in vitro. Trop Med Parasitol 39: 145-148.
8. Cruz FS, Marr JJ, Berens RL, 1980. Prevention of transfusion-induced Chagas' disease by amphotericin B. Am J Trop Med Hyg 29: 761-765.
9. Horvath AE, Zierdt CH, 1974. The effect of amphotericin B on Trypanosoma cruzi in vitro and in vivo. J Trop Med Hyg 77: 144-149.
10. Tachibana H, Kurihara K, Nagakura K, Kaneda Y, Montenegro LT, 1985. Therapeutic effect of hachimycin in Trypanosoma cruzi infected mice. IRCS Med Sci 13: 1108-1109.
11. Bolard J, Vertut-Doi A, 1995. Internalization of amphotericin B and other polyene antifungals in mammalian cell: a possible origin of their toxicity. Georgopapadakou NH, ed. Drug Transport in Antimicrobial and Anticancer Chemotherapy. New York: Marcel Dekker Inc., 307-326.
12. Brajtburg J, Bolard J, 1996. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 9: 512-531.
13. Legrand P, Vertut-Doi D, Bolard J, 1996. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 37: 519-533.
14. Janknegt R, van Etten EWM, de Marie S, 1996. Lipid formulations of amphotericin B. Curr Opin Infect Dis 9: 403-406.
15. Hiemenz JW, Walsh TJ, 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22 (suppl 2): 133-144.
16. Berman JD, Ksionski G, Chapman WL, Waits VB, Hanson WL, 1992. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother 36: 1978-1980.
17. Croft SL, Davidson RN, Thornton EA, 1991. Liposomal aphotericin B in the treatment on visceral leishmaniasis. J Antimicrob Chemother 28 (suppl): 111-118.
18. Gangneux J-P, Sulahain A, Garin YJ-F, Farinotti R, Derouin F, 1996. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 40: 1214-1218.
19. Mullen AB, Carter KC, Bailie AJ, 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 41: 2089-2092.
20. Dietze R, Fagundes SMS, Brito EF, Milan EP, Feitosa TF, Suassuna FAB, Fonschiffrey G, Ksionski G, Dember J, 1995. Treatment of kala-azar in Brazil with Amphocil® (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Med Hyg 89: 309-311.
21. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson ADM, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
22. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW, 1997. Short course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 127: 133-137.
23. Yardley V, Croft SL, 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 41: 752-756.
24. Hartsel S, Bolard J, 1996. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 17: 445-449.
25. Barwicz J, Christian S, Gruda I, 1992. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 36: 2310-2315.
26. Bennet JE, Hill GJ, Butler WT, Chester WE, 1963. Correlation of particle size of intravenous amphotericin B with toxic and chemotherapeutic effect. Antimicrob Agents Chemother 3: 745-752.
27. Bolard J, Legrand P, Cbulska B, 1991. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30: 5707-5715.
28. Gaboriau F, Chéron M, Petit C, Bolard J, 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother 41: 2345-2351.
29. Wasan KM, Lopez-Berestein G, 1994. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target 2: 373-380.
30. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G, 1994. Decreased toxicity of liposomal amphotericin B due to association of amphotercin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83: 1006-1010.
31. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ, 1992. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23: 279-291.
32. Bhamra R, Sa'ad A, Bolcsak LE, Janoff AS, Swenson CE, 1997. Behaviour of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 41: 886-892.
33. Rinninger F, Greten H, 1990. High-density lipoprotein particle uptake and selective uptake of high-density lipoprotein-associated cholesteryl esters by J774 macrophages. Biochim Biophys Acta 1043: 318-326.
34. Legrande P, Cheron M, Leroy L, Bolard J, 1997. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Target 4: 311-319.
35. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G, 1990. Amphotericin B: delivery systems. Antimicrob Agents Chemother 34: 381-384.
36. Miller GJ, Miller NE, 1975. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1: 16-19.